All articles published by MDPI are made immediately available worldwide under an open access license. No special
permission is required to reuse all or part of the article published by MDPI, including figures and tables. For
articles published under an open access Creative Common CC BY license, any part of the article may be reused without
permission provided that the original article is clearly cited. For more information, please refer to
https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature
Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for
future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive
positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world.
Editors select a small number of articles recently published in the journal that they believe will be particularly
interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the
most exciting work published in the various research areas of the journal.
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
Department of Lung Diseases and Tuberculosis, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland
2
Pulmonology Department, Public Clinical Hospital No. 1 in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland
*
Author to whom correspondence should be addressed.
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with poor prognosis. Although the underlying mechanisms are not fully understood, IPF is connected with lung cancer development, which farther worsens the prognosis. Various papers report IPF and cancer coexistence in 9.8% to over 50% of patients depending on observation period. Contrary to already established guidelines in the general population, there are no widely accepted recommendations on lung cancer treatment in IPF population. At the same time, various oncologic interventions can result in acute exacerbation of IPF. In this paper authors tried to revise the available data on lung cancer in patients with preexisting IPF.
Zieliński, M.; Sitek, P.; Ziora, D.
Idiopathic Pulmonary Fibrosis Coexisting with Lung Cancer. Adv. Respir. Med.2018, 86, 319-326.
https://doi.org/10.5603/ARM.a2018.0052
AMA Style
Zieliński M, Sitek P, Ziora D.
Idiopathic Pulmonary Fibrosis Coexisting with Lung Cancer. Advances in Respiratory Medicine. 2018; 86(6):319-326.
https://doi.org/10.5603/ARM.a2018.0052
Chicago/Turabian Style
Zieliński, Michał, Piotr Sitek, and Dariusz Ziora.
2018. "Idiopathic Pulmonary Fibrosis Coexisting with Lung Cancer" Advances in Respiratory Medicine 86, no. 6: 319-326.
https://doi.org/10.5603/ARM.a2018.0052
Article Metrics
No
No
Article Access Statistics
For more information on the journal statistics, click here.
Multiple requests from the same IP address are counted as one view.
Zieliński, M.; Sitek, P.; Ziora, D.
Idiopathic Pulmonary Fibrosis Coexisting with Lung Cancer. Adv. Respir. Med.2018, 86, 319-326.
https://doi.org/10.5603/ARM.a2018.0052
AMA Style
Zieliński M, Sitek P, Ziora D.
Idiopathic Pulmonary Fibrosis Coexisting with Lung Cancer. Advances in Respiratory Medicine. 2018; 86(6):319-326.
https://doi.org/10.5603/ARM.a2018.0052
Chicago/Turabian Style
Zieliński, Michał, Piotr Sitek, and Dariusz Ziora.
2018. "Idiopathic Pulmonary Fibrosis Coexisting with Lung Cancer" Advances in Respiratory Medicine 86, no. 6: 319-326.
https://doi.org/10.5603/ARM.a2018.0052